Home
CMMB
CMMB News

Latest Chemomab Therapeutics Ltd. (CMMB) News on November 28, 2025

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

GlobeNewswire

4 days ago

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire

8 days ago

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

GlobeNewswire

22 days ago

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

Zacks

a month ago

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study

Zacks

a month ago

SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

Zacks

a month ago

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan

Zacks

a month ago

Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

Zacks

a month ago

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals

Zacks

a month ago

TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

Zacks

2 months ago

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data

Zacks

2 months ago

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

Zacks

2 months ago

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study

Zacks

2 months ago

AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

GlobeNewswire

5 months ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

GlobeNewswire

6 months ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

GlobeNewswire

6 months ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire

6 months ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

GlobeNewswire

7 months ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

Biotech Alert: Searches spiking for these stocks today

TipRanks

7 months ago

Biotech Alert: Searches spiking for these stocks today

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

GlobeNewswire

7 months ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

GlobeNewswire

7 months ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Announces New Medical and Clinical Appointments

GlobeNewswire

7 months ago

Chemomab Announces New Medical and Clinical Appointments

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

GlobeNewswire

8 months ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis

GlobeNewswire

9 months ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire

9 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

GlobeNewswire

9 months ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

10 months ago

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

GlobeNewswire

a year ago

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

GlobeNewswire

a year ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

GlobeNewswire

a year ago

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

GlobeNewswire

a year ago

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Chemomab Therapeutics to Present at October 2024 Investor Conferences

GlobeNewswire

a year ago

Chemomab Therapeutics to Present at October 2024 Investor Conferences

Chemomab Therapeutics to Present at September 2024 Investor Conferences

GlobeNewswire

a year ago

Chemomab Therapeutics to Present at September 2024 Investor Conferences

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

GlobeNewswire

a year ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

GlobeNewswire

a year ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

GlobeNewswire

a year ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Chemomab Therapeutics Announces $10 Million Private Placement

GlobeNewswire

a year ago

Chemomab Therapeutics Announces $10 Million Private Placement

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

GlobeNewswire

a year ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

GlobeNewswire

a year ago

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

GlobeNewswire

a year ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

GlobeNewswire

2 years ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

2 years ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

GlobeNewswire

2 years ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

GlobeNewswire

2 years ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

GlobeNewswire

2 years ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

GlobeNewswire

2 years ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

GlobeNewswire

2 years ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

GlobeNewswire

2 years ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

PR Newswire

2 years ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

PR Newswire

2 years ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

PR Newswire

2 years ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

PR Newswire

2 years ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

PR Newswire

2 years ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

AG Mortgage Investment Trust, Inc. Announces Tax Treatment of 2023 Distributions

Business Wire

2 years ago

AG Mortgage Investment Trust, Inc. Announces Tax Treatment of 2023 Distributions

Janover Named 2024 Commercial Real Estate Tech Influencer by GlobeSt.com

GlobeNewswire

2 years ago

Janover Named 2024 Commercial Real Estate Tech Influencer by GlobeSt.com

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

PR Newswire

2 years ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

LENSAR Decline Means Insider Profits Down To US$42k

Simply Wall St.

2 years ago

LENSAR Decline Means Insider Profits Down To US$42k

D-Wave Joins Forces with Deloitte Canada to Advance Quantum Adoption

Business Wire

2 years ago

D-Wave Joins Forces with Deloitte Canada to Advance Quantum Adoption

Ronny Yakov Bought 17% More Shares In OLB Group

Simply Wall St.

2 years ago

Ronny Yakov Bought 17% More Shares In OLB Group

Calculating The Intrinsic Value Of Rent the Runway, Inc. (NASDAQ:RENT)

Simply Wall St.

2 years ago

Calculating The Intrinsic Value Of Rent the Runway, Inc. (NASDAQ:RENT)

Alaska credit union to buy $1.5B-asset Washington bank

Banking Dive

2 years ago

Alaska credit union to buy $1.5B-asset Washington bank

Trust Stamp ® Announces that Forty-Five customers started or completed integration with the Company’s Orchestration Layer by the end of 2023

GlobeNewswire

2 years ago

Trust Stamp ® Announces that Forty-Five customers started or completed integration with the Company’s Orchestration Layer by the end of 2023

Ohmyhome and Webuy Announce Strategic Collaboration to Cross-Sell Products and Services Across Singapore

GlobeNewswire

2 years ago

Ohmyhome and Webuy Announce Strategic Collaboration to Cross-Sell Products and Services Across Singapore

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire

2 years ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

GlobeNewswire

2 years ago

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

PR Newswire

2 years ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

WANG & LEE GROUP First Half 2023 Earnings: US$0.11 loss per share (vs US$0.032 loss in 1H 2022)

Simply Wall St.

2 years ago

WANG & LEE GROUP First Half 2023 Earnings: US$0.11 loss per share (vs US$0.032 loss in 1H 2022)

Bright Scholar Filed Annual Report on Form 20-F for Fiscal 2023

PR Newswire

2 years ago

Bright Scholar Filed Annual Report on Form 20-F for Fiscal 2023

Business Wire

2 years ago

SIFCO Industries, Inc. ("SIFCO") Announces Fourth Quarter and Full Year Fiscal 2023 Financial Results

Royce Global Value Trust (NYSE: RGT) as of Nov 30, 2023

PR Newswire

2 years ago

Royce Global Value Trust (NYSE: RGT) as of Nov 30, 2023

Bright Scholar Announces Results of 2024 Annual General Meeting

PR Newswire

2 years ago

Bright Scholar Announces Results of 2024 Annual General Meeting

Movano Health Announces HSA/FSA Eligibility for its Women First Wearable, The Evie Ring

PR Newswire

2 years ago

Movano Health Announces HSA/FSA Eligibility for its Women First Wearable, The Evie Ring

One Hennessy Advisors Insider Raised Their Stake In The Previous Year

Simply Wall St.

2 years ago

One Hennessy Advisors Insider Raised Their Stake In The Previous Year

Associated Press Finance

2 years ago

Enzo Biochem: Fiscal Q1 Earnings Snapshot

ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

GlobeNewswire

2 years ago

ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

Is There An Opportunity With Traeger, Inc.'s (NYSE:COOK) 45% Undervaluation?

Simply Wall St.

2 years ago

Is There An Opportunity With Traeger, Inc.'s (NYSE:COOK) 45% Undervaluation?

MARPAI, INC. ANNOUNCES APPOINTMENT OF TWO NEW INDEPENDENT DIRECTORS

PR Newswire

2 years ago

MARPAI, INC. ANNOUNCES APPOINTMENT OF TWO NEW INDEPENDENT DIRECTORS

SYLA Technologies Updates 2023 Full Year Financial Guidance with Upward Revision of Income from Continuing Operations and Earnings Per Share

GlobeNewswire

2 years ago

SYLA Technologies Updates 2023 Full Year Financial Guidance with Upward Revision of Income from Continuing Operations and Earnings Per Share

Blackboxstocks, Inc. Signs Definitive Agreement to Acquire Evtec Aluminium, Supplier of Proprietary Parts for the EV, Hybrid, and Performance Automotive Market, with Projected Revenue of US$52 Million for Fiscal Year Ending June 30, 2024

Business Wire

2 years ago

Blackboxstocks, Inc. Signs Definitive Agreement to Acquire Evtec Aluminium, Supplier of Proprietary Parts for the EV, Hybrid, and Performance Automotive Market, with Projected Revenue of US$52 Million for Fiscal Year Ending June 30, 2024

Many Still Looking Away From OceanPal Inc. (NASDAQ:OP)

Simply Wall St.

2 years ago

Many Still Looking Away From OceanPal Inc. (NASDAQ:OP)

17 Education & Technology Group Inc. Announces Third Quarter 2023 Unaudited Financial Results

GlobeNewswire

2 years ago

17 Education & Technology Group Inc. Announces Third Quarter 2023 Unaudited Financial Results

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

GlobeNewswire

2 years ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Express, Inc. (NYSE:EXPR) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Express, Inc. (NYSE:EXPR) Q3 2023 Earnings Call Transcript

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to January 3, 2024

GlobeNewswire

2 years ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to January 3, 2024

Deion "Coach Prime" Sanders Named 2023 Sports Illustrated Sportsperson of the Year

Business Wire

2 years ago

Deion "Coach Prime" Sanders Named 2023 Sports Illustrated Sportsperson of the Year

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

ACCESSWIRE

2 years ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Inseego Appoints SVP of Global Channel Sales and Distribution

Business Wire

2 years ago

Inseego Appoints SVP of Global Channel Sales and Distribution

Business Wire

2 years ago

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

CVG Announces Participation in the NobleCon19 Investor Conference

GlobeNewswire

2 years ago

CVG Announces Participation in the NobleCon19 Investor Conference

Business Wire

2 years ago

ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference

Returns On Capital Are Showing Encouraging Signs At NL Industries (NYSE:NL)

Simply Wall St.

2 years ago

Returns On Capital Are Showing Encouraging Signs At NL Industries (NYSE:NL)

Director Michael Thompson's Strategic Insider Purchase of AuthID Inc Shares

GuruFocus.com

2 years ago

Director Michael Thompson's Strategic Insider Purchase of AuthID Inc Shares

Cineverse Inks Global Commercial YouTube Channel Agreement with Little Dot Studios

PR Newswire

2 years ago

Cineverse Inks Global Commercial YouTube Channel Agreement with Little Dot Studios

authID Inc. Announces Pricing of Approximately $9.4 Million Registered Direct Offering

GlobeNewswire

2 years ago

authID Inc. Announces Pricing of Approximately $9.4 Million Registered Direct Offering

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

PR Newswire

2 years ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q3 2023 Earnings Call Transcript

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

PR Newswire

2 years ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Associated Press Finance

2 years ago

Northern Dynasty: Q3 Earnings Snapshot

Share on Social Networks: